After investigators selected chemotherapy ( pegylated liposomal doxorubicin , weekly paclitaxel , or topotecan ) , patients were randomly assigned to single-agent chemotherapy alone or with bevacizumab ( @ mg/kg every @ weeks or @ mg/kg every @ weeks ) until progression , unacceptable toxicity , or consent withdrawal .